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Background: Vulvar carcinoma is an infrequent tumour, accounting for fewer than 3% of all malignant tumours
that affect women, but its incidence is rising in the past few decades. In young women, the manifestation of the
vulvar carcinoma is often linked to risk factors such as smoking and HPV infection, but most cases develop in
women aged over 50 years through poorly understood genetic mechanisms. Rho-associated coiled-coil-containing
protein kinase 1 (ROCK1) has been implicated in many cellular processes, but its function in vulvar cancer has never
been examined. In this study, we aimed to determine the prognostic value of ROCK1 gene and protein analysis in
vulvar squamous cell carcinoma (VSCC).
Methods: ROCK1 expression levels were measured in 16 vulvar tumour samples and adjacent normal tissue by
qRT-PCR. Further, 96 VSCC samples were examined by immunohistochemistry (IHC) to confirm the involvement of
ROCK1 in the disease. The molecular and pathological results were correlated with the clinical data of the patients.
Sixteen fresh VSCC samples were analyzed by array-based comparative genomic hybridization (aCGH).
Results: In each pair of samples, ROCK1 levels were higher by qRT-PCR in normal tissue compared with the tumour
samples (p = 0.016). By IHC, 100% of invasive front areas of the tumour and 95.8% of central tumour areas were
positive for ROCK1. Greater expression of ROCK1 was associated with the absence of lymph node metastasis (p = 0.022)
and a lower depth of invasion (p = 0.002). In addition, higher ROCK1 levels correlated with greater recurrence-free
survival (p = 0.001). Loss of ROCK1 was independently linked to worse cancer-specific survival (p = 0.0054) by
multivariate analysis. This finding was validated by IHC, which demonstrated enhanced protein expression in normal
versus tumour tissue (p < 0.001). By aCGH, 42.9% of samples showed a gain in copy number of the ROCK1 gene.
Conclusions: ROCK1 is lower expressed in tumour tissue when compared with adjacent normal vulvar epithelia. In an
independent sample set of VSCCs, lower expression levels of ROCK1 correlated with worse survival rates and a poor
prognosis. These findings provide important information for the clinical management of vulvar cancer.
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Vulvar carcinoma is an infrequent tumour, accounting
for 3% to 5% of all cancers of the female genital system
[1-3]. Its incidence rises with age, peaking in women
aged between 65 and 75 years [4,5].
Vulvar squamous cell carcinoma (VSCC) constitutes
90% of all malignant vulvar tumours and has 2 clinico-
pathological types. The first type arises primarily in youn-
ger patients and is associated with human papillomavirus
(HPV) infection; the other form is seen mostly in elderly
patients and appears to develop independently of HPV in-
fection. These types of VSCC have disparate epidemio-
logical, clinical, pathological, and molecular characteristics
[3,4,6]. Despite its rarity, the incidence of VSCC has been
rising in the past several decades, necessitating the identi-
fication of predictive factors of its prognosis.
Changes in cellular dynamics induce morphological al-
terations in cells, due to reorganization of the actin cyto-
skeleton. The Rho family of small GTPases are central
regulators of the dynamics and reorganization of the
actin cytoskeleton, mediating the formation of stress fi-
bers and focal adhesions [7-9]. Certain members of the
Rho family, such as RhoA and RhoC, interact with down-
stream targets, culminating in various cellular responses.
Their principal activity is to promote actomyosin contract-
ility by phosphorylating a specific serine/threonine kinase,
Rho-kinase associated coiled-coil (ROCK).
ROCK1 and 2 have been implicated in many cellular
processes and pathologies, particularly in metastatic pro-
cesses of cell lines and in the cardiovascular and nervous
systems. Based on their oncogenic activity, ROCKs are
being examined as therapeutic targets in various tumours,
such as non-small-cell lung tumours [10]; glioblastoma
[11]; osteosarcoma [12]; and prostate [13,14], breast [15],
ovarian [16], hepatocellular [17], and bladder cancers [18].
Human ROCK1 maps to chromosome 18 (18q11.1)
[19-22] and performs its functions by phosphorylating
substrates, such as myosin light chain (MLC), the MLC
phosphatase subunit (MYPT-1), and LIM kinase; many
other substrates continue to be reported. These sub-
strates catalyze many processes during morphological
changes and metastasis, including structural rearrange-
ment, adhesion, alterations in cellular polarity, migra-
tion, invasion, transformation, proliferation, cytokinesis,
and apoptosis [9,22,23].
The precise function of ROCK1 in carcinogenesis
and in the architectural rearrangement of tumour cells
during metastasis remains debated [24]. ROCK1 ap-
pears to be implicated in a complex balance between
oncogene function and proapoptotic responses, de-
pending on the cell type. Based on its involvement in
cell migration in other tumours and the lack of data on
its function in vulvar carcinomas, we selected ROCK1
for further study.We aimed to examine the function of ROCK1 in the
progression of vulvar carcinoma. In this study, we mea-
sured ROCK1 mRNA and protein levels and analyzed the
data on ROCK1 copy number alterations from a parallel
project of our group. The transcript and protein results
were correlated with clinicopathological characteristics to
determine the prognostic value of ROCK1 in vulvar
cancer.
Methods
Patient and sample selection
A total of 96 invasive vulvar carcinoma samples were
randomly and retrospectively selected from the archives
of the AC Camargo Cancer Center Anatomic Pathology
Department from January 1990 to December 2010 and
analyzed by immunohistochemistry. All samples were
formalin-fixed and paraffin-embedded (FFPE), and their
HPV status has been reported [2,5,25]. Sixteen fresh fro-
zen tumour samples and 11 adjacent nontumour sam-
ples were also obtained from the AC Camargo Cancer
Center Biobank for mRNA expression and DNA copy
number analysis.
The inclusion criteria were patients who had under-
gone surgery or biopsy in this hospital and were diag-
nosed with invasive vulvar squamous cell carcinoma. All
cases were H&E-stained and reviewed by experienced
pathologists to confirm the previous diagnosis and adapt
the reports to updated nomenclature. The clinical data
on all patients were obtained from their medical records.
In situ carcinomas, cases in which neoadjuvant radio-
therapy and/or chemotherapy were performed, and cases
that lacked sufficient material or clinical information for
the analyses were excluded from the study.
This work was approved by the ethics committee at
AC Camargo (Research Ethics Committee number 1672/
12) and was performed per the Helsinki Declaration.
RNA extraction from fresh frozen samples
The RNeasy Mini Kit RNA Extraction Kit (QIAGEN,
Austin, TX, USA) and a Precellys® 24 homogenizer
(Stretton Scientific, Stretton, UK) were used to extract
RNA from the fresh frozen samples per the manufac-
turer’s instructions. Prior to the extraction, the H&E
slides from all samples were reviewed by the Biobank’s
chief pathologist (Dr. AHJFMC). Aliquots of RNA were
stored at -80°C until cDNA synthesis.
Quantitative real-time RT-PCR (RT-qPCR)
Gene expression was analyzed by RT-qPCR on an
Applied Biosystems 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) using the
TaqMan Universal PCR Master Mix detection system
(Applied Biosystems), according to the supplier’s specifica-
tions. Primers and probes for ROCK1 (Hs01127688_m1)
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used as an endogenous control. Data analyses were per-
formed, comparing adjacent normal and tumorous vul-
var samples. The Pfaffl [26] method was used to obtain
relative quantification (RQ) values and determine gene
expression levels [26].
Immunohistochemistry
Four-micrometer-thick FFPE samples were placed on
StarFrost® electrically charged slides (Braunschweig,
Germany). All reactions were performed on whole-tissue
slides using the Advance Kit Protocol (DAKO). Antigen
recovery was performed using Tris-EDTA (pH 9.0) in a
water bath (96°C). The primary antibody was anti-
ROCK1 (ABCAM, Cat.#1761-1, Clone EP786Y), diluted
1:100. At the end of the reaction, the slides were washed
with tap water, dehydrated sequentially in alcohol and
xylene, and mounted manually.
Evaluation of immunohistochemistry
Slides were digitalized on an APERIO® scanner and
scored visually. IHC expression patterns were evaluated
quantitatively, wherein expression levels were scored by
the percentage of positive cells and the intensity of im-
munostaining [HScore = Σ (ix Pi) and Pi: percentage of
positive pixels, ranging from 0% to 100% and color in-
tensity of the pixel i =0, 1, 2, or 3], ranging between 20
and 250 per Rodrigues et al. [25]. Final HScores were
defined as HScore =1 when the positivity was weak, with
staining intensity ranging from 20 to 149 and HScore =2
for strong staining and a staining intensity of ≥150.
ROCK1 immunostaining was present in all samples.
Two areas for each case—the central tumour and inva-
sive front—were examined for ROCK1 expression. As
described (Rodrigues et al. [25]), the central tumour was
considered as the largest area of extension of the
tumour; at least 3 areas were selected and analyzed. The
invasive front was defined as a group of up to 5 cells
that detached from the main tumour mass, which usu-
ally infiltrated the adjacent stroma; 10 fields were se-
lected [25].
Array based-comparative genomic hybridization array
(aCGH)
Based on our ROCK1/mRNA and protein data, we ex-
amined ROCK1 copy number alterations in vulvar car-
cinoma samples by array-CGH using data from a
parallel study. A total of 200 ng each of tumour DNA
and normal commercially available DNA (Human Genomic
DNA: Female; Promega, Madison, USA) were analyzed
compared on an 8 × 60 K Agilent platform for aCGH
(Agilent Technologies®, Santa Clara, USA).
The labeling, hybridization, and washes were per-
formed per the Agilent Oligonucleotide Array-BasedCGH for Genomic DNA Analysis – Enzymatic Labeling
kit protocol (Agilent Technologies®, Santa Clara, USA).
The slides were scanned on a DNA microarray scanner
with Surescan High-Resolution Technology (Agilent Tech-
nologies®, Santa Clara, USA), based on HG19, and the
results were extracted using Feature Extraction, v10.7.3.1
(Agilent Technologies®, Santa Clara, USA). Copy number
analysis was performed using Nexus Copy Number Soft-
ware, v6.0 (Biodiscovery, El Segundo, USA).
A copy number alteration was defined as exceeding the
significance threshold of 1 × 10−6 in a minimum of 5 con-
secutive probes and in more than 30% of the samples.
Thresholds were defined as the average log2 CGH
fluorescence ratio for copy gains ≥0.3, high copy number
gains defined as ≥0.6, losses defined as ≤ -0.3, and homo-
zygous losses defined as ≤ -1.0. Nonrandom genomic
copy number alterations were identified using the Fast
Adaptive States Segmentation Technique 2 (FASST2) al-
gorithm and the Significance Testing for Aberrant Copy
number (STAC) statistical method [27,28]. Alterations
that were detected in at least 42.9% of samples were ex-
amined in greater detail.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS, IBM), version 20.0.
Protein expression in the tumour center and invasive front
was compared by Wilcoxon signed-rank test. Mann-
Whitney test and student t-test were used to analyze the
association between protein expression and clinicopatho-
logical parameters, and the Kaplan-Meier method was
used to examine specific cancer survival and recurrence-
free survival rates. The difference between survival curves
was assessed by log-rank test. Multivariate analyses were
performed using the Cox proportional hazards regression
model. Statistical significance was set to p ≤0.05.
Results
Demographic and clinicopathological features
The mean age of the 96 patients was 75 years, ranging
from 30 to 103 years. The mean age at menopause was
50 years, ranging between 38 and 60 years. Most pa-
tients were Caucasian (83.3%) and did not consume al-
cohol (88.5%); 15.6% of patients were current or past
smokers.
Forty eight percent of the patients were HPV-positive,
most of whom had the subtypes HPV16 (48%), HPV33
(24%), and HPV18 (15%). Associated lesions were present,
such as vulvar intraepithelial neoplasias (VINs; 13.5% of
patients) and lichen sclerosus (6.25%). Based on the histo-
logical diagnosis, moderately differentiated squamous cell
carcinomas (SCC2) was the most prevalent form (46%),
followed by SCC1 (34%), basaloid (9%), SCC3 (8%), sarco-
matoid (2%), and verrucous carcinoma (1%). Most tumours
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IIIB (20.3%), IIIA (12.1%), II (6.2%), IIIC (6.2%), and IVA
(2.1%). Of the 96 patients with VSCC, 34.4% died due to
the cancer, and 46.9% expired due to other causes.ROCK1 mRNA expression
By RT-qPCR, ROCK1 was overexpressed in normal adja-
cent samples compared with the tumour tissue (p = 0.0167,
Figure 1A). Also, ROCK1 HScores were higher in normal
epithelium versus the tumour areas in a subset of samples
(n = 21) (p < 0.001) (Figure 1B, C, and D).ROCK1 immunostaining
ROCK1 immunostaining was heterogeneous and cyto-
plasmic in all tumour extensions (Figure 2) and positive
in the invasive front of all cases (100%) and in 92 central
tumours (95.8%). There was a significant positive correl-
ation between central tumour and invasive front expres-
sion of ROCK1 (p <0.001; Figure 3A).
In the statistical analysis, greater expression of ROCK1
in central tumours and the invasive front correlated
significantly with the absence of lymph node metastasis
(p = 0.036 and p = 0.022, respectively), the presence of
inflammatory infiltrate (p =0.010 and p = 0.009, respectively),
and a lower depth of invasion (p = 0.048 and p =
0.002), as shown in Figure 3B. There was no associationFigure 1 ROCK 1 mRNA and protein are overexpressed in normal tiss
samples compared with tumour samples (p =0.016, A). Increased ROCK1 im
a subset of samples (n = 21) (B); p <0.001. Representative images of norma
captured at 400× magnification.between ROCK1 positivity and HPV infection, histological
type, FIGO stage, recurrence, or vascular invasion.
ROCK1 expression and patient survival
Patients with lower expression of ROCK1 in the central
tumour and invasive front had lower recurrence-free
survival rates (p = 0.004 and p = 0.001, respectively;
Figure 4A and B), and those with weak ROCK1 expression
in the invasive front experienced lower cancer-specific
survival (p <0.001; Figure 4C and D). By multivariate
analysis, high ROCK1 expression in the invasive front was
independently associated with greater cancer-specific
survival (HR 0.3, 95% CI 0.11–0.84, p = 0.0054; Table 1).
The clinicopathological characteristics were analyzed
by Cox regression. Lymph node metastasis (data not
shown) and vascular invasion were independently asso-
ciated with decreased of the survival (p = 0.0074 and
0.0365, respectively).
aCGH analysis
By aCGH analysis, 29 regions underwent significant copy
number alterations: 9 were associated with copy number
loss (8p23.3, 5q11.1-q11.2, 3p11.1-q11.1, 9p23, 21p11.2-
p11.1, Xq28, 7q36.3, 19p13.3, and 21p11.2), and 20 had
gains (1q22, 20q11.21-q11.23, 1p36.23-p36.22, 11q13.3,
19q13.12, 19q13.32, 7q11.21, 7q11.22, 7q11.23, 7q11.23,
7q22.1, 11q12.2-q12.3, 11q12.3, 11q13.2, 16q22.1, 18q11.1-ues. ROCK1 is overexpressed by qRT-PCR analysis in normal adjacent
munostaining HScore in normal epithelium compared with tumour in
l epithelium (C) and tumour (D) immunostaining from the same case,
Figure 2 Immunohistochemical staining of ROCK1 in vulva carcinoma. Representative image of weak-positive staining in central tumour
(A) and invasive front (B, arrows); moderate staining in the central tumour (C) and invasive front (D, arrows); strong-positive staining in central
magnification. Images A and B were captured at 200× magnification. Images C, D, E, and F were captured at 400× magnification.
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q11.2). Of the latter, region 18q11.1-q11.2, which harbors
ROCK1, had more copies than the reference DNA in
42.9% of samples (Figure 5).
To identify their function and the processes that they
mediate, the genes that were selected in the copy number
analysis were included in an in silico functional analysis,
performed by Ingenuity Pathways Analysis (IPA). ROCK1
appeared in 2 of the top 5 canonical pathways with the
highest ratios—RhoGDI and Rho GTP signaling—both of
which are associated with cell migration.
Discussion
ROCK has significant functions in cancer progression and
metastasis, rendering it a potential therapeutic target [9].
In this study, we examined the function of the Rho-
associated protein kinase ROCK1 in human vulvar carcin-
oma. Our data showed that aspects that are related to a
good prognosis, such as the absence of lymph node me-
tastasis, lower depth of invasion, and better survival, cor-
related with ROCK1 immunoexpression, suggesting that
ROCK1 is a marker of good prognosis in vulvar cancer.ROCK1 immunopositivity was observed in the tumour
invasion fronts of all cases and in nearly all central
tumour areas. Also, there was no difference in ROCK1
expression levels between central tumour versus invasive
front areas, in contrast to what we have reported con-
cerning the variability of epithelial to mesenchymal
transition markers [26], EGFR [29], and c-Kit [5] in tu-
mours. Nevertheless, vulvar carcinomas can be highly
heterogeneous [29,30], and cytoplasmic immunostain-
ing for ROCK1 protein was heterogeneous in all
tumour extensions in our cases, reflecting a disadvan-
tage of ROCK-targeting therapies in this tumour type.
In this study, we performed a global evaluation of
ROCK1 expression and its relationship with clinical data
and the prognosis. ROCK has a significant influence on
cancer progression [8,9,11,31], metastasis [17,21,32,33],
and apoptosis [12,23,34]. Recent evidence suggests that
ROCK phosphorylates PTEN [34,35], a negative regula-
tor of the PI3-K/Akt pathway, with roles in cell survival
and apoptosis [34,36].
Inhibition of ROCK/Rho-kinase in Ras-transformed
cells is insufficient to effect a motile phenotype in them,
Figure 3 Association between clinicopathological features and ROCK1 in vulvar carcinoma. Abbreviations: ≤2 = 2 or fewer lymph nodes
involved; >2 =more than 2 lymph nodes involved; SMD = superficial and mid-dermis; DDA = deep dermis and subcutaneous tissues. *Statistically
significant, p < 0.05.
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Figure 4 Kaplan-Meier survival curves for ROCK1 staining. Increased expression of ROCK1 in the central tumour (p =0.004; A) and in the
invasive front (p =0.001; B) correlates with better recurrence-free survival and lower cancer-specific survival in the central tumour (p =0.081; C)
and in the invasive front (p <0.001; D). Abbreviations: CT = central tumour; IF = invasive front.
Table 1 Multivariate analysis of ROCK1 expression and clinicopathological characteristics in patients with vulvar SCC
Variables Category n Hazard ratio for survival 95.0% CI p
Histologic types SCC1, SCC2, Verrucous Ca (1) 76 1 1 0.6177
SCC3, Basaloid Ca, Sarcomatoid Ca(2) 20 0.78 0.30 - 2.05
FIGO stage IA, IB, II (1) 54 1 1 0.2083
IIA, IIIB, IIIC, IVA, IVB (2) 40 1.62 0.76 - 3.47
HPV Absent (0) 50 1 1 0.2238
Present (1) 46 0.63 0.30 - 1.33
Inflammatory infiltrate Absent (0) 38 1 1 0.4964
Present (1) 58 0.77 0.36 - 1.64
Vascular Invasion Absent (0) 74 1 1 0.0365*
Present (1) 17 2.22 1.03 - 4.77
Perineural invasion Absent (0) 76 1 1 0.4178
Present (1) 12 1.43 0.60 - 3.38
ROCK1 CT Weak expression 22 1 1 0.6653
Moderate expression 55 0.70 0.28 - 1.75
Strong expression 19 0.95 0.34 - 2.67
ROCK1 IF Weak expression 8 1 1 0.0054*
Moderate expression 53 0.22 0.08 - 0.60
Strong expression 35 0.30 0.11 -0.84
Abbreviations: SCC squamous cell carcinomas, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, HPV human papillomavirus,
SMD superficial and mid dermis, DDA deep dermis and subcutaneous tissues, CT central tumour and IF invasive front. *Statistically significant, p < 0.05.
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Figure 5 Representative image of aCGH analysis of chromosome 18 with emphasis on ROCK1. (A) The copy number gain
(chr18:18,539,853-19,429,001) is in blue; exons of ROCK1 are illustrated at the bottom of the diagram. (B) Example highlighting the gains (≥0.3) in
blue and high gains (≥0.6) in yellow. Gene regions covered by each probe can be seen as small dots.
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regulators of the cytoskeleton to increase its motility
[32]. Notably, elongated cells, such as SW-962, a vulvar
squamous cell carcinoma metastatic cell line do not re-
quire Rho or ROCK function, unlike cells that move
through rounded, or amoeboid, movement [21,37,38].
Thus, we hypothesize that elongated vulvar carcinoma
cells move and migrate using mechanisms other than
Rho/ROCK activation. The effectiveness of therapeutic
agents against ROCK, such as fusadil and Y27632, might
be limited when cells move through elongated morph-
ology [37].
ROCK1 immunostaining was also associated with im-
portant clinical features in vulvar cancer and with the
most significant clinical property and prognostic factor
in this tumour: lymph node metastasis. When overex-
pressed, ROCK1 correlated inversely with lymph node
metastasis in the central tumour and invasive front. To
define groups for the statistical analysis regarding the
clinical implications of the presence or absence of lymph
node involvement, we considered positivity as metastasis
when 2 or more lymph nodes were involved and negativ-
ity when 1 or 0 lymph nodes were involved. This strat-
egy was based on a previous study that demonstrated
that 5-year survival for patients with negative or 1 posi-
tive lymph node did not differ from each other [39].
Similarly, greater expression in the central tumour and
invasive front was associated with lower invasive depth
and higher recurrence-free survival.
Clinicopathological characteristics analyzed by Cox re-
gression demonstrated that lymph node metastasis and
vascular invasion were independently associated with de-
creased of the survival, indicating that these features are
related to poor survival in patients with VSCC. Also,
higher expression of ROCK1 was linked to greatersurvival, the absence of lymph node metastasis, and a
lower depth of invasion. Moreover, elevated ROCK1
levels in the invasive front was an independent pro-
tective factor (HR =0.22 for moderate expression, and
HR =0.33 for strong expression) with regard to cancer-
specific survival (p =0.0054).
These results implicate ROCK1 as a good prognostic
marker in vulvar cancer. In addition, patients with weak
expression of ROCK1 in the invasive front, but not the
central tumour, had lower cancer-specific survival rates,
implying that this marker is protective during cancer
progression. Conversely, ROCK1 has been largely re-
ported as a marker of worse prognosis in many cancer
types [12].
There is emerging evidence that ROCK governs the
morphological events that take place during apoptosis
(cell contraction, membrane blebbing, nuclear fragmen-
tation, and disintegration of apoptotic cells) through
cytoskeletal rearrangement and actomyosin contractility
[40,41]. Other groups contend that ROCK1 is required
for apoptotic fragmentation and phagocytosis of dying
COS-7 cells [41]. Because ROCK is a proapoptotic regu-
lator in various cell types, depending on the cell type
and apoptotic stimulus [40], we believe that its overex-
pression in vulvar cancer is associated with apoptotic
stimuli and, thus, it can be associated with better prog-
nosis; as demonstrated in other studies [41,42]. Although
the relationship between apoptosis and the prognosis re-
mains unknown, it could, at least in part, explain the as-
sociation of ROCK1 with a good prognosis in vulvar
cancer.
ROCK1 copy number gains were detected in 42.9% of
our samples. However, these data are controversial, be-
cause ROCK1 was more highly expressed in normal tis-
sue by IHC and RT-qPCR compared with tumour
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and gene expression comprise the concomitant amplifi-
cation of the gene with enhancement of its expression,
there remain other genes, approximately 50% [43], the
amplification of which does not correspond to gene
overexpression.
We hypothesize that tissues that were used for
normalization of the validation techniques were adjacent
to the tumour. Despite careful morphological analysis by
an experienced pathologist of nontumour tissue, the
proximity of malignant cells could have influenced the
surrounding microenvironment, upregulating various
genes, including ROCK1, in normal epithelia.
In addition, other mechanisms, such as microRNA
regulation and epigenetic alterations (including methyla-
tion and histone deacetylation), might cause the lack of
correlation between the genomic and proteomic data
found in our study. Previous reports have demonstrated
the function of microRNAs (eg, microRNA-135a and
microRNA124-3p) in ROCK1 regulation in prostate, gas-
tric, and bladder carcinoma [44-46].
Also, despite the increase in copy number in tumour
samples by aCGH analysis, we can not make any conclu-
sions regarding gene integrity and the extent of its ab-
normal. Our results do not allow us to conclude much
concerning the amplification of ROCK1 in the tumour
samples or on the possible generation of aberrant mRNA
or truncated protein. The genomic mechanism that leads
to gene amplification in tumour cells remains undefined,
as do the molecular pathways that effect amplified gene
expression.
Conclusions
This is the first report to demonstrate that ROCK1 cor-
relates with a good prognosis in cancer. Although vulvar
carcinomas are rare, this type of cancer can serve as a
valuable model in the study of molecular alterations that
can be transposed to other types of epithelial neoplasms.
Further, novel biomarkers, such as ROCK1, are signifi-
cant, because its evaluation by IHC in routine practice
can help better establish prognosis and select more con-
servative surgical approaches for this mutilating disease.
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